Management Reports • May 14, 2012
Management Reports
Open in ViewerOpens in native device viewer
News Details
Corporate | 14 May 2012 20:11
STRATEC extends financial guidance for 2012 to 2014
STRATEC Biomedical AG / Key word(s): Results Forecast/Forecast
14.05.2012 / 20:11
STRATEC extends financial guidance for 2012 to 2014
– **Sales of between EUR 125 million and EUR 139 million expected in 2012
– Average sales growth (CAGR) of between 14% and 16% expected over the period 2012 to 2014 based on 2011 sales (EUR 116.6 million)
– Current production run rates and planned market launches give reason to expect sales to meet or potentially exceed the EUR 160 million mark in 2013
– EBIT margin of between 17% and 19% in 2012 and 2013**
Birkenfeld, May 14, 2012
STRATEC Biomedical AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, TecDAX) hereby publishes its company forecast for the 2012 to 2014 financial years, taking due account of the latest developments in the in-vitro diagnostics industry, additional customer information, and updated internal assessments.
STRATEC expects to generate sales of between EUR 125 million and EUR 139 million in 2012. Furthermore, average sales growth (CAGR) over the period 2012 to 2014 is expected to amount to 14% to 16% based on 2011 sales (EUR 116.6 million). Based on current production run rates and planned market launches, STRATEC still expects to achieve, and potentially exceed, the EUR 160 million sales mark originally expected for 2013. The company expects to generate an EBIT margin of between 17% and 19% in 2012 and 2013.
The long-term planning of market launches and the minimum volume commitments, and rolling acceptance forecasts on the part of its customers, mean that STRATEC enjoys a high degree of transparency concerning its performance. Medium-term forecasting is influenced by ongoing consolidation in the diagnostics industry, planned market launches, approval dates – which can only be anticipated to a limited extent – and analyzer system generation changes. Due to scaling effects and given that the relative margin contribution from the business with replacement parts is spread over several financial years, the earnings corridor has been defined very broadly (gross margin influenced by both growth of sales and margin contribution of replacement parts). STRATEC is currently still increasing its development expenditures to account for further projects, both newly acquired or in an advanced negotiation stage.
About STRATEC
STRATEC Biomedical AG ( www.stratec.com ) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
End of Corporate News
14.05.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | STRATEC Biomedical AG |
| Gewerbestr. 37 | |
| 75217 Birkenfeld | |
| Germany | |
| Phone: | +49 (0)7082 7916 0 |
| Fax: | +49 (0)7082 7916 999 |
| E-mail: | [email protected] |
| Internet: | www.stratec.com |
| ISIN: | DE0007289001 |
| WKN: | 728900 |
| Indices: | TecDAX |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart |
| End of News | DGAP News-Service |
| - - - |
| 169839 14.05.2012 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.